# An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

> **NCT00532194** · PHASE3 · UNKNOWN · sponsor: **Medical Research Council** · enrollment: 486 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** cediranib

## Key facts

- **NCT ID:** NCT00532194
- **Lead sponsor:** Medical Research Council
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-07
- **Primary completion:** 2013-04
- **Final completion:** 2016-12
- **Target enrollment:** 486 (ACTUAL)
- **Last updated:** 2015-09-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532194, "An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00532194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*